Development of niosome-loaded bromelain as anti-inflammatory agent
Loading...
Date
2015
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Universiti Teknologi Malaysia
Abstract
Inflammation can be considered as common human being anxiousness. Nonsteroidal anti-inflammatory drugs (NSAIDS) are usually prescribed to reduce inflammation but they may lead to serious side-effects. Recently anti-inflammatory property of bromelain have been documented, but oral administration of bromelain requires higher concentration as compared to topical delivery. Hence, topical delivery of bromelain as a more favorable anti-inflammatory solution for skin inflammation, but it has to overcome stratum corneum (SC) skin barrier. The aims of this study were to design a bromelain delivery system based on niosome and to evaluate the efficacy of the bromelain-niosome system. Moreover, anti-inflammatory effect of niosome encapsulated bromelain was studied by Interleukin-6 (IL-6) and Tumor Necrotic Factor–alpha (TNF-a) response. This potential anti-inflammatory property of niosome encapsulated bromelain was investigated in-vitro and in-vivo, using human skin fibroblast cell line (HSF 1184) and mice, respectively. Lipopolysaccharide (LPS) was used in volume of 1.5 µg/mL in-vitro and 7.5 µg/mL in-vivo to induce inflammation. The current results showed that 20 µg/mL niosome encapsulated with 10% bromelain after four hours of post treatment significantly eliminated inflammation in HSF 1184 cell line as compared to non-encapsulated bromelain, vehicle (niosome), and controls. Similar result was achieved in mice where 20 mg niosome encapsulated with 10% bromelain was found able to eliminate inflammation after 30 minutes of post treatment. In conclusion, this research provides scientific evidence to show effective transdermal delivery of niosome encapsulated bromelain to reach targeted dermal cells and show its pharmaceutical potential to eliminate skin inflammation.
Description
Thesis (PhD. (Bioprocess Engineering))
Keywords
Anti-Inflammatory Agents—analysis, Bromelin, Skin—Inflammation